{"entity":{"id":"nct07165886","kind":"trial","name":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","aka":[],"tldr":"A phase 2/3 trial of Everolimus in pancreatic ductal adenocarcinoma, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.","summary":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors is a phase 2/3 interventional study registered as NCT07165886 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 298 participants planned, started 2025-08-29 and due to reach its primary completion in 2028-08-29. Interventions recorded: Sirolimus for injection (albumin bound), Octreotide long-acting injection and Everolimus.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07165886","url":"https://clinicaltrials.gov/study/NCT07165886"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["kinase-inhibitors","pi3k-akt-mtor-inhibitors"],"targets":[],"drugs":["everolimus"],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07165886","phase":"2/3","setting":"Phase II/III Study to Evaluate the Safety and Efficacy of Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","participation":[{"nct":"NCT07165886","source":"https://clinicaltrials.gov/study/NCT07165886","fetchedAt":"2026-10-07T16:55:29.886Z","studySha256":"3fe4a87a5c00fd631e8005376c7804c8ff7c00812e787c7eca3004c9bac895b6","overallStatus":"RECRUITING","lastUpdatePosted":"2026-04-24","leadSponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":298,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-08-29","startedType":"actual","enrolled":298,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07165886/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"pi3k-akt-mtor-inhibitors","kind":"technology","name":"PI3K, AKT and mTOR inhibitors","route":"/technologies/pi3k-akt-mtor-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}]}}